A Phase 1 interventional study of Tenapanor in Lactation, sponsored by Ardelyx. Completed at 2 sites in United States. Open to female participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-11.
Sponsored by Ardelyx · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 251 studies in Breast Feeding with a site in United States — 44 open to participants now, 49 under way, none of them phase 3. Breast Feeding · United States.
Among the 251 studies in Breast Feeding with a site in United States, this one is the 180th largest by enrollment of the 202 interventional ones that give a count, is one of 13 that started in 2023, is one of 8 in phase 1, and was the 208th registered.
1,082 studies on the registry are indexed under Breast Feeding; 217 are open to participants now.
Browse Breast Feeding studies →44 of the 251 studies in Breast Feeding with a site in United States are open now. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 18+ · Women only
University of Illinois at Urbana-Champaign · Sites in United States
Ages 21–45 · Women only · Healthy volunteers
Eli Lilly and Company · Sites in United States, Canada, Denmark and 4 more countries
Ages 3 wk+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18–50 · Women only
University of Colorado, Denver · Sites in United States
Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 127 Breast Feeding studies recruiting now, 66 (52%) set no upper age limit and 59 (46%) stop at 75 or younger; 53 take children under 18; 76 take healthy volunteers.
This study: 18 Years to 60 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
251 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 6 · Phase 4 14
First in 2000; this study’s year is marked. 13 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 7 is below the median of 100 across 845 interventional studies indexed under Breast Feeding.
Median enrollment 83 across the 202 interventional studies, 88 across the 49 observational. Of the 180 that completed or were terminated, 46 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 251 have an industry lead sponsor. The 10 most frequent:
Ardelyx is the lead sponsor of 29 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 4 (50%) have results posted.
Ardelyx has 1 study filed under Breast Feeding — fewer than ten, so there is no comparison to draw.
15 of the studies in Breast Feeding with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07176793University of California, DavisPregnancy and Postpartum Breastfeeding Support for Patients With Gestational Diabetes | 2026-12-30 |
| NCT05457972University Hospitals Cleveland Medical CenterPostpartum Vaginal Estrogen for Breastfeeding Patients | 2026-12-31 |
| NCT06107933Johns Hopkins Bloomberg School of Public HealthDevelopmental Impacts of Microplastics Exposure in Early Life | 2026-12-31 |
| NCT05441709Endeavor HealthFurthering Equity Through Infant Feeding EDucation and Support | 2026-12-31 |
| NCT03838536University of North Carolina, Chapel HillSynergistic Activity of Human Milk Nutrients and Infant Cognition | 2027-03 |
Add all 15 to your calendar (.ics) → With an account.
Among the 251 studies in Breast Feeding with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.
This will be an open-label study to investigate the PK of tenapanor and AZ13792925 in breast milk of lactating female subjects. Potential subjects will be screened to assess their eligibility to enter the study within 15 days prior to the first dose administration. Subjects will receive tenapanor from Days 1 to 4 and will be monitored for 24 hours after the last dose of tenapanor. On Day 4, breast milk to evaluate concentrations of tenapanor and AZ13792925 will be collected pre-dose (Hour 0), 1, 2, 4, 6, 8, and 24 hours post-dose. Subjects will return for a Follow-up visit, 5 to 7 days (Day 10±1) after the last dose. All breast milk not used for PK analyses will be discarded (not fed to infant) starting on Day 1 after the first dose of tenapanor is administered until Day 7 (72 hours after last dose of tenapanor).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy all of the following criteria at the Screening visit unless otherwise stated:
Exclusion Criteria:
Subjects will be excluded from the study if they satisfy any of the following criteria at the Screening visit unless otherwise stated:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible subjects will be enrolled to receive the study drug
Drug: Tenapanor
The study drug will be administered in dose of 50 mg bid
Also known as: IBSRELA
Concentration of tenapanor and its major metabolite in breast milk
The primary objective of the study is to determine the maximum observed milk concentration (Cmax) of tenapanor and its primary metabolite AZ13792925 in the breast milk of lactating female subjects.
Time frame: 26 Days
The safety of tenapanor in lactating females
The secondary objective of the study is to assess the the incidence and severity of treatment-emergent adverse events of tenapanor when administered to lactating female subjects.
Time frame: 26 Days
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in May 2024, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tenapanor